This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Compounds of the formula I



I

in which

D denotes an aromatic five-membered heterocyclic ring having 1 to 4 N, O and/or S atoms which is unsubstituted or mono- or polysubstituted by Hal, A, OR^2, $N(R^2)_2$, NO_2, CN, $COOR^2$ or $CON(R^2)_2$,

X denotes NR^3 or O,

R^1 denotes H, Ar, Het, cycloalkyl or A, which may be substituted by OR^2, SR^2, $N(R^2)_2$, Ar, Het, cycloalkyl, CN, $COOR^2$ or $CON(R^2)_2$,

R^2 denotes H, A, $-[C(R^3)_2]_n$-Ar, $-[C(R^3)_2]_n$-Het, $-[C(R^3)_2]_n$-cycloalkyl, $-[C(R^3)_2]_n-N(R^3)_2$ or $-[C(R^3)_2]_n-OR^3$,

R^3 denotes H or A,

W denotes $-[C(R^3)_2]_n-$,

Y denotes alkylene, cycloalkylene, Het-diyl or Ar-diyl,

T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocyclic ring having 0 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, $-[C(R^3)_2]_n$-Ar, $-[C(R^3)_2]_n$-Het, $-[C(R^3)_2]_n$-cycloalkyl, OR^3, $N(R^3)_2$, NO_2, CN, $COOR^2$, $CON(R^2)_2$, NR^2COA, $NR^2CON(R^2)_2$, NR^2SO_2A, COR^2, SO_2NR^2 and/or $S(O)_mA$ and/or carbonyl oxygen,
or $N(R^2)_2$
and, if Y = piperidine-1,4-diyl, also R^2 or cycloalkyl,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by

-CH=CH- groups and/or also 1-7 H atoms may be replaced by F,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^3, $N(R^3)_2$, NO_2, CN, $COOR^3$, $CON(R^3)_2$, NR^3COA, $NR^3CON(R^3)_2$, NR^3SO_2A, COR^3, $SO_2N(R^3)_2$, $S(O)_mA$, $-[C(R^3)_2]_n-COOR^{2'}$ or $-O-[C(R^3)_2]_o-COOR^{2'}$,

$R^{2'}$ denotes H, A, $-[C(R^3)_2]_n-Ar'$, $-[C(R^3)_2]_n-Het'$, $-[C(R^3)_2]_n$-cycloalkyl, $-[C(R^3)_2]_n-N(R^3)_2$ or $-[C(R^3)_2]_n-OR^3$,

$R^{2''}$ denotes H, A, $-[C(R^3)_2]_n-Ar'$ or $-[C(R^3)_2]_n$-cycloalkyl, $-[C(R^3)_2]_n-N(R^3)_2$ or $-[C(R^3)_2]_n-OR^3$,

Ar' denotes phenyl or benzyl, each of which is unsubstituted or mono- or disubstituted by Hal or A,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, =S, $=N(R^3)_2$, Hal, A, $-[C(R^3)_2]_n-Ar$, $-[C(R^3)_2]_n-Het^1$, $-[C(R^3)_2]_n$-cycloalkyl, $-[C(R^3)_2]_n-OR^{2'}$, $-[C(R^3)_2]_n-N(R^{2'})_2$, NO_2, CN, $-[C(R^3)_2]_n-COOR^{2'}$, $-[C(R^3)_2]_n-CON(R^{2'})_2$, $-[C(R^3)_2]_n-NR^{2'}COA$, $NR^{2'}CON(R^{2'})_2$, $-[C(R^3)_2]_n-NR^{2'}SO_2A$, $COR^{2'}$, $SO_2NR^{2'}$ and/or $S(O)_mA$,

Het^1 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, =S, $=N(R^3)_2$, Hal, A, $OR^{2''}$, $N(R^{2''})_2$, NO_2, CN, $COOR^{2''}$, $CON(R^{2''})_2$, $NR^{2''}COA$, $NR^{2''}CON(R^{2''})_2$, $NR^{2''}SO_2A$, $COR^{2''}$, $SO_2NR^{2''}$ and/or $S(O)_mA$,

Hal denotes F, Cl, Br or I,

n denotes 0, 1 or 2,

m denotes 0, 1 or 2,

o denotes 1, 2 or 3,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Original) Compounds according to Claim 1,
in which

D denotes an aromatic five-membered heterocyclic ring having 1 to 2 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

3. (Currently Amended) Compounds according to Claim 1 ~~or 2~~,
in which

D denotes a thienyl ring which is mono- or disubstituted by Hal,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

4. (Currently Amended) Compounds according to ~~one or more of Claims 1-3~~ Claim 1, in which

R^2 denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

5. (Currently Amended) Compounds according to ~~one or more of Claims 1-4~~ Claim 1, in which

R^1 denotes H or unsubstituted phenyl, thienyl or alkyl having 1-6 C atoms,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

6. (Currently Amended) Compounds according to ~~one or more of Claims 1-5~~ Claim 1, in which

X denotes NH or O,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

7. (Currently Amended) Compounds according to ~~one or more of Claims 1-6~~ Claim 1, in which

W denotes $(CH_2)_n$,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

8. (Currently Amended) Compounds according to ~~one or more of Claims 1-7~~ Claim 1, in which

Y denotes Ar-diyl or Het-diyl,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

9. (Currently Amended) Compounds according to ~~one or more of Claims 1-8~~ Claim 1, in which

T denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen,
or $N(R^2)_2$
and, if Y = piperidine-1,4-diyl, also R^2,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

10. (Currently Amended) Compounds according to ~~one or more of Claims 1-9~~ Claim 1, in which

T denotes a mono- or bicyclic saturated or unsaturated heterocyclic ring having 1 to 2 N and/or O atoms which is mono- or disubstituted by carbonyl oxygen (=O),
or $N(R^2)_2$
and, if Y = piperidine-1,4-diyl, also R^2,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

11. (Currently Amended) Compounds according to ~~one or more of Claims 1-10~~ Claim 1, in which

T denotes piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, each of which is mono- or disubstituted by carbonyl oxygen,
or $N(R^2)_2$
and, if Y = piperidine-1,4-diyl, also R^2,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

12. (Currently Amended) Compounds according to ~~one or more of Claims 1-11~~ Claim 1, in which

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO_2A, $COOR^2$, SO_2NH_2 or CN,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

13. (Currently Amended) Compounds according to ~~one or more of Claims 1-12~~ Claim 1, in which

D denotes an aromatic five-membered heterocyclic ring having 1 to 2 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal,

R^1 denotes H or unsubstituted phenyl, thienyl or alkyl having 1-6 C atoms,

R^2 denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X denotes NH or O,

W denotes W $(CH_2)_n$,

Y denotes Ar-diyl, pyridinediyl or piperidinediyl,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO_2A, $COOR^2$, SO_2NH_2 or CN,

T denotes piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, each of which is mono- or disubstituted by carbonyl oxygen,
or $N(R^2)_2$
and, if Y = piperidine-1,4-diyl, also R^2,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

14. (Currently Amended) Compounds according to ~~one or more of Claims 1-13~~ Claim 1, in which

D denotes thienyl, thiazolyl or furyl, each of which is mono- or disubstituted by Hal,

R^1 denotes H or unsubstituted phenyl, thienyl or alkyl having 1-6 C atoms,

R^2 denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X denotes NH or O,

W denotes W $(CH_2)_n$,

Y denotes Ar-diyl, pyridinediyl or piperidinediyl,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO_2A, $COOR^2$, SO_2NH_2 or CN,

T denotes piperidin-1-yl, pyrrolidin-1-yl, pyridinyl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazinyl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, each of which is unsubstituted or mono- or disubstituted by carbonyl oxygen,
or $N(R^2)_2$

and, if Y = piperidine-1,4-diyl, also R^2,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

15. (Original) Compounds according to Claim 1 selected from the group

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-3-methylphenyl]valeramide,

2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]acetamide,

(R)-2-[3-(5-bromothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[3-(5-bromofuran-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]-2-phenylacetamide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]-2-(thiophen-2-yl)acetamide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(2-oxopiperidin-1-yl)-phenyl]valeramide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(2-oxo-1*H*-pyrazin-1-yl)-phenyl]valeramide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[2-oxo-3,4,5,6-tetrahydro-[1,2']bipyridinyl-5'-yl]valeramide,

(S)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]-2-phenylacetamide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenylmethyl]valeramide,

(R)-2-[3-(5-chlorothiazol-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[N-(5-chlorothiophen-2-yl)carbamoyloxy]-N-[[4-(3-oxo-morpholin-4-yl)phenyl]valeramide,

(R)-2-[*N*-(5-chlorothiophen-2-yl)carbamoyloxy]-*N*-[*C*-(3,4,5,6-tetrahydro-2*H*-[1,4']bipyridinyl-4-yl)methyl]valeramide,

(R)-2-[N-(5-chlorothiophen-2-yl)carbamoyloxy]-N-[1-isopropyl-piperidin-4-ylmethyl]-2-phenylacetamide,

(R)-2-[N-(5-chlorothiophen-2-yl)carbamoyloxy]-N-[[4-(morpholin-4-yl)-phenyl]valeramide

(R)-2-[N-(5-chlorothiophen-2-yl)carbamoyloxy]-N-(4-dimethylamino-phenyl)-2-phenylacetamide

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

16. (Currently Amended) Process for the preparation of compounds of the formula I according to ~~Claims 1-15~~ Claim 1 and pharmaceutically usable derivatives, solvates and stereoisomers thereof, characterised in that

a) a compound of the formula II



II

in which

R^1, W, X, Y and T have the meaning indicated in Claim 1,

is reacted with a compound of the formula III

D-N=C=O III

in which

D has the meaning indicated in Claim 1,

or

b) a compound of the formula IV

$$H_2N\text{-}W\text{-}Y\text{-}T \qquad IV$$

in which W, Y and T have the meaning indicated in Claim 1,

is reacted with a compound of the formula V



V

in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group, and

R^1, X and D have the meanings indicated in Claim 1,

and/or

a base or acid of the formula I is converted into one of its salts.

17. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 15~~ Claim 1 as inhibitors of coagulation factor Xa.

18. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 15~~ Claim 1 as inhibitors of coagulation factor VIIa.

19. (Currently Amended) Medicaments comprising at least one compound of the formula I according to ~~one or more of Claims 1 to 15~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including

mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

20. (Currently Amended) Medicamens comprising at least one compound of the formula I according to ~~one or more of Claims 1 to 15~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

21. (Currently Amended) Use of compounds according to ~~one or more of Claims 1 to 15~~ Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases.

22. (Currently Amended) Set (kit) consisting of separate packs of

(a) an effective amount of a compound of the formula I according to ~~one or more of Claims 1 to 15~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and

(b) an effective amount of a further medicament active ingredient.

23. (Currently Amended) Use of compounds of the formula I according to ~~one or more of Claims 1 to 15~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, in combination with at least one further medicament active ingredient.